Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZR6E
|
|||
| Drug Name |
TVI-Brain-1 cancer vaccine
|
|||
| Indication | Astrocytoma [ICD-11: 2A00.0Y] | Phase 2 | [1] | |
| Brain cancer [ICD-11: 2A00] | Phase 2 | [2] | ||
| Glioma [ICD-11: 2A00.0] | Phase 2 | [3] | ||
| Pneumococcal infection [ICD-11: CA00-CA40] | Phase 2 | [3] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1] | ||
| Company |
TVAX Biomedical Olathe, KS
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01290692) Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.